These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19875570)

  • 1. Should white-coat hypertension in diabetes be treated? Pro.
    Mancia G; Sega R; Bombelli M; Quarti-Trevano F; Facchetti R; Grassi G
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S305-9. PubMed ID: 19875570
    [No Abstract]   [Full Text] [Related]  

  • 2. White-coat hypertension should not be treated in subjects with diabetes.
    Bursztyn M; Ben-Dov IZ
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S310-3. PubMed ID: 19875571
    [No Abstract]   [Full Text] [Related]  

  • 3. Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes?
    Parati G; Bilo G
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S298-304. PubMed ID: 19875569
    [No Abstract]   [Full Text] [Related]  

  • 4. [Is prevalence of the "white coat effect" correlated with a high risk of late diabetic complications in type 2 diabetic patients?].
    Mozdzan M; Ruxer J; Barański M; Roszczyk N; Markuszewski L
    Ann Acad Med Stetin; 2008; 54(1):65-9; discussion 69. PubMed ID: 19127812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'White coat' hypertension. No harm for the heart.
    Gosse P; Promax H; Durandet P; Clementy J
    Hypertension; 1993 Nov; 22(5):766-70. PubMed ID: 8225536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study.
    MacGregor AS; Price JF; Hau CM; Lee AJ; Carson MN; Fowkes FG
    Diabetes Care; 1999 Mar; 22(3):453-8. PubMed ID: 10097928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic and metabolic profile in offspring of malignant hypertensive parents.
    Lopes HF; Bortolotto LA; Szlejf C; Kamitsuji CS; Krieger EM
    Hypertension; 2001 Sep; 38(3 Pt 2):616-20. PubMed ID: 11566942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension in diabetes.
    Diabetes Care; 1993 Oct; 16(10):1394-401. PubMed ID: 8269800
    [No Abstract]   [Full Text] [Related]  

  • 9. Variations of ambulatory blood pressure with position in patients with type 1 diabetes: influence of disease duration and microangiopathy in a pilot study.
    Benhamou PY; Mouret S; Quesada JL; Boizel R; Baguet JP; Halimi S; Mallion JM
    Diabetes Care; 2001 Sep; 24(9):1624-8. PubMed ID: 11522710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of white-coat hypertension on microvascular complications in type 2 diabetes: response to Kramer et al.
    Eguchi K; Kario K
    Diabetes Care; 2009 Feb; 32(2):e24; author reply e25. PubMed ID: 19171733
    [No Abstract]   [Full Text] [Related]  

  • 11. Blood pressure variability in patients with diabetes mellitus.
    Mokhtar RH; Ayob A; Mohd Noor N
    Asian Cardiovasc Thorac Ann; 2010 Aug; 18(4):344-8. PubMed ID: 20719784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction: hypertension and diabetes. Critical combination for micro- and macrovascular disease.
    Viberti GC; Messent J
    Diabetes Care; 1991 Nov; 14 Suppl 4():4-7. PubMed ID: 1748057
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros?
    Segura J; Ruilope LM
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S284-9. PubMed ID: 19875566
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
    El-Bassossy HM; Abo-Warda SM; Fahmy A
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):643-9. PubMed ID: 22594672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological expression in the microcirculation: hypertension and diabetes.
    Bohlen HG
    Physiologist; 1982 Aug; 25(4):391-5. PubMed ID: 7146122
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential glucose tolerance in dipper and nondipper essential hypertension: the implications of circadian blood pressure regulation on glucose tolerance in hypertension.
    Chen JW; Jen SL; Lee WL; Hsu NW; Lin SJ; Ting CT; Chang MS; Wang PH
    Diabetes Care; 1998 Oct; 21(10):1743-8. PubMed ID: 9773741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes.
    Rodrigues TC; Canani LH; Viatroski RS; Hoffmann LH; Esteves JF; Gross JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):240-5. PubMed ID: 19926157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in type 2 diabetic subjects.
    Thomsen C; Rasmussen OW; Hansen KW; Vesterlund M; Hermansen K
    Diabet Med; 1995 Jul; 12(7):600-6. PubMed ID: 7554782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right ventricular dysfunction in asymptomatic diabetic patients.
    Kosmala W; Colonna P; Przewlocka-Kosmala M; Mazurek W
    Diabetes Care; 2004 Nov; 27(11):2736-8. PubMed ID: 15505015
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulse pressure is more susceptible to the white coat effect than is systolic blood pressure: observations from real-life ambulatory blood pressure monitoring.
    Ben-Dov IZ; Perk G; Ben-Arie L; Mekler J; Bursztyn M
    Am J Hypertens; 2004 Jun; 17(6):535-9. PubMed ID: 15177528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.